BP
DMAC icon

Ballentine Partners’s DiaMedica Therapeutics DMAC Stock Holding History

Ballentine Partners’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$289K Buy
+41,012
New +$252K ﹤0.01% 811

Other funds holding DMAC

MW
Members Wealth Media, Pennsylvania $182M AUM 15.09% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Ballentine Partners's DMAC Position: Q2 2026 in Review

Ballentine Partners opened a new position in DiaMedica Therapeutics (DMAC) in Q2 2026: 41,012 shares worth $289K. The stake represents ﹤0.01% of the portfolio and ranks #811 among its holdings.

6 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Ballentine Partners held 41,012 shares of DiaMedica Therapeutics worth $289K as of Q2 2026.
  • DiaMedica Therapeutics was a new Ballentine Partners position in Q2 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Ballentine Partners's portfolio in Q2 2026, its #811 holding.
  • 6 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.